The median forecasts in this calendar come from surveys of economists conducted by Dow Jones Newswires and The Wall Street Journal. All statistics in this calendar are in expressed in nominal terms ...
Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback